Molecular and Clinical Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
PLoS One. 2010 Jul 7;5(7):e11414. doi: 10.1371/journal.pone.0011414.
Anecdotal information and case reports suggest that intravenously administered vitamin C is used by Complementary and Alternate Medicine (CAM) practitioners. The scale of such use in the U.S. and associated side effects are unknown.
We surveyed attendees at annual CAM Conferences in 2006 and 2008, and determined sales of intravenous vitamin C by major U.S. manufacturers/distributors. We also queried practitioners for side effects, compiled published cases, and analyzed FDA's Adverse Events Database. Of 199 survey respondents (out of 550), 172 practitioners administered IV vitamin C to 11,233 patients in 2006 and 8876 patients in 2008. Average dose was 28 grams every 4 days, with 22 total treatments per patient. Estimated yearly doses used (as 25 g/50 ml vials) were 318,539 in 2006 and 354,647 in 2008. Manufacturers' yearly sales were 750,000 and 855,000 vials, respectively. Common reasons for treatment included infection, cancer, and fatigue. Of 9,328 patients for whom data is available, 101 had side effects, mostly minor, including lethargy/fatigue in 59 patients, change in mental status in 21 patients and vein irritation/phlebitis in 6 patients. Publications documented serious adverse events, including 2 deaths in patients known to be at risk for IV vitamin C. Due to confounding causes, the FDA Adverse Events Database was uninformative. Total numbers of patients treated in the US with high dose vitamin C cannot be accurately estimated from this study.
High dose IV vitamin C is in unexpectedly wide use by CAM practitioners. Other than the known complications of IV vitamin C in those with renal impairment or glucose 6 phosphate dehydrogenase deficiency, high dose intravenous vitamin C appears to be remarkably safe. Physicians should inquire about IV vitamin C use in patients with cancer, chronic, untreatable, or intractable conditions and be observant of unexpected harm, drug interactions, or benefit.
一些传闻和病例报告表明,补充和替代医学(CAM)从业者会静脉注射维生素 C。但目前尚不清楚此类应用在美国的规模以及相关的副作用。
我们调查了 2006 年和 2008 年 CAM 年会的与会者,并确定了美国主要制造商/分销商的静脉注射维生素 C 的销售情况。我们还向从业者查询了副作用,汇编了已发表的病例,并分析了 FDA 的不良事件数据库。在 199 名调查对象(550 名中的)中,有 172 名从业者在 2006 年为 11233 名患者和 2008 年为 8876 名患者静脉注射维生素 C。平均剂量为每 4 天 28 克,每位患者共进行 22 次治疗。根据(25 克/50 毫升小瓶)估计每年使用的剂量为 2006 年 318539 剂和 2008 年 354647 剂。制造商的年销售额分别为 75 万和 85.5 万瓶。治疗的常见原因包括感染、癌症和疲劳。在有数据的 9328 名患者中,有 101 名出现副作用,大多为轻微副作用,包括 59 名患者出现乏力/疲劳、21 名患者出现精神状态改变和 6 名患者出现静脉刺激/静脉炎。文献记录了严重的不良事件,包括 2 名已知有静脉注射维生素 C 风险的患者死亡。由于混杂因素,FDA 的不良事件数据库没有提供有用的信息。由于本研究存在局限,因此无法准确估计美国使用大剂量维生素 C 治疗的患者总数。
CAM 从业者广泛使用高剂量静脉注射维生素 C。除了肾功能损害或葡萄糖-6-磷酸脱氢酶缺乏的患者静脉注射维生素 C 已知的并发症外,高剂量静脉注射维生素 C 似乎非常安全。对于患有癌症、慢性、无法治疗或顽固性疾病的患者,医生应询问患者是否使用过静脉注射维生素 C,并注意观察意外伤害、药物相互作用或获益。